Boston Partners raised its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 2.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,007,100 shares of the company's stock after purchasing an additional 125,611 shares during the quarter. Cencora comprises 1.4% of Boston Partners' holdings, making the stock its 4th biggest position. Boston Partners owned approximately 2.59% of Cencora worth $1,128,058,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of the stock. Hickory Asset Management Inc. acquired a new stake in shares of Cencora in the fourth quarter worth $572,000. Sylvest Advisors LLC acquired a new stake in shares of Cencora in the fourth quarter worth $1,105,000. Insight Wealth Strategies LLC increased its stake in shares of Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock worth $4,549,000 after acquiring an additional 11,232 shares during the period. Cerity Partners LLC increased its stake in shares of Cencora by 10.1% in the third quarter. Cerity Partners LLC now owns 39,457 shares of the company's stock worth $8,881,000 after acquiring an additional 3,610 shares during the period. Finally, Vontobel Holding Ltd. increased its stake in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after acquiring an additional 1,995 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.
Insider Transactions at Cencora
In related news, CEO Robert P. Mauch sold 4,970 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now directly owns 51,070 shares in the company, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,970 shares of company stock valued at $2,998,670. Corporate insiders own 10.80% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on COR. Wells Fargo & Company increased their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Evercore ISI increased their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Mizuho assumed coverage on shares of Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target on the stock. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Finally, JPMorgan Chase & Co. increased their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $280.20.
Check Out Our Latest Research Report on Cencora
Cencora Price Performance
COR traded down $0.93 during midday trading on Friday, hitting $266.91. 6,526,576 shares of the company traded hands, compared to its average volume of 1,376,560. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The company has a market capitalization of $51.76 billion, a price-to-earnings ratio of 37.97, a PEG ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $271.08. The business has a 50 day simple moving average of $250.62 and a two-hundred day simple moving average of $240.06.
Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.
Cencora Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.82%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.
Cencora Profile
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
